Insider Buying: Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Buys $25,187.50 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Karthik Radhakrishnan bought 1,550 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was acquired at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Monopar Therapeutics Trading Up 0.4 %

Shares of Monopar Therapeutics stock opened at $14.63 on Friday. Monopar Therapeutics Inc. has a 52 week low of $1.37 and a 52 week high of $38.50. The company’s 50-day moving average price is $6.17 and its two-hundred day moving average price is $4.34. The stock has a market cap of $57.93 million, a PE ratio of -6.36 and a beta of 1.26.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Friday, August 9th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, equities analysts predict that Monopar Therapeutics Inc. will post -1.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MNPR has been the subject of a number of research analyst reports. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright upped their target price on Monopar Therapeutics from $2.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.